Neurodegeneration in patients with Type 2 Diabetes Mellitus without Diabetic Retinopathy by Garcia-Martin, Elena et al.
Research Article
Neurodegeneration in Patients with Type 2 Diabetes
Mellitus without Diabetic Retinopathy
Elena Garcia-Martin ,1,2 Marta Cipres,1,2 Isabel Melchor,3 Laura Gil-Arribas,1,2
Elisa Vilades,1,2 Vicente Polo,1,2 Maria Jesus Rodrigo ,1,2 and Maria Satue 1,2
1Ophthalmology Department, Miguel Servet University Hospital, Zaragoza, Spain
2Miguel Servet Ophthalmology Research Group (GIMSO), Aragon Health Research Institute (IIS Aragon), Zaragoza, Spain
3Endocrinology Department, Miguel Servet University Hospital, Zaragoza, Spain
Correspondence should be addressed to Maria Satue; mariasatue@gmail.com
Received 11 April 2019; Revised 22 June 2019; Accepted 1 July 2019; Published 7 August 2019
Academic Editor: Pierluigi Iacono
Copyright © 2019 Elena Garcia-Martin et al. (is is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
Purpose. To evaluate neurodegeneration in patients with type 2 diabetes mellitus (DM2) without diabetic retinopathy and to assess
the possible role of systemic vascular complications in retinal changes.Methods. Sixty eyes of 60 patients with DM2 and without
any signs of diabetic retinopathy and 60 eyes of 60 healthy controls underwent retinal evaluation using Spectralis optical co-
herence tomography. Macular ganglion cell layer (GCL) and retinal nerve fiber layer (RNFL) were evaluated. Peripapillary RNFL
thickness was assessed using Glaucoma and Axonal Analytics applications. Comparison between patients with the presence/
absence of systemic vascular complications and different disease duration was made. Results. Macular GCL was reduced in
patients compared to controls (p< 0.001). Differences in the macular RNFL thickness were only observed in the outer inferior
sector (p � 0.033). A reduction in the peripapillary RNFL (average, inferior, and inferotemporal thickness, p< 0.05 for all three)
was observed in patients using both applications. Patients with chronic systemic vascular complications presented a reduction in
the temporal RNFL (p � 0.019) compared to patients without complications. (e superotemporal RNFL thickness was thinner in
patients with longer disease duration. Conclusions. Patients with type 2 DM without diabetic retinopathy and good metabolic
control present neurodegeneration affecting neurons in the macular area and axons in different sectors of the optic disc. Systemic
vascular complications contributed to further axonal damage in these patients, suggesting a possible role of subclinical ischaemia
to retinal neurodegeneration in type 2 DM.
1. Introduction
Diabetic retinopathy in patients with diabetes mellitus (DM)
was typically considered part of a vascular process. However,
recent research suggested that retinal degeneration in DM
might be caused not only by vasculopathy but also (and
importantly) by neuropathy [1]. For some authors, neu-
ropathy observed in the retina of DM patients might be just
part of an underlying polyneuropathy [2, 3]; for others,
however, neuropathic changes might precede microvascular
alterations [4].
In the past decade, studies evaluating the neuroretina of
DM patients using optical coherence tomography (OCT)
technology tried to discern whether alterations affecting the
retinal nerve fiber layer (RNFL) and other retinal layers
preceded any vascular changes in these patients. Un-
fortunately, results were far from consistent.
Macular evaluation in DM patients might be biased by
the presence of incipient edema, masking neuronal loss. (e
peripapillary area contains a higher density of axons (RNFL)
compared to the macular area, and therefore, it should be
considered an optimal location to evaluate axonal loss in
these patients.
(e purpose of the present study was to evaluate neu-
rodegeneration in the macular (total thickness, ganglion cell
layer thickness, and retinal nerve fiber layer thickness) and
peripapillary (RNFL thickness) areas of patients with type 2
DM (DM2) without diabetic retinopathy (i.e., retinal
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vascular alterations or macular edema) and to assess the
possible role of metabolic control, disease duration, and
systemic vascular complications (ischaemia) on retinal
changes in these patients.
2. Methods
We recruited sixty patients with type 2 DM and 60 age- and
sex-matched healthy controls for the study. All procedures
adhered to the tenets of the Declaration of Helsinki, and the
local ethics committee (CEICA, ethics committee for sci-
entific research in Aragon) approved the experimental
protocol. All participants provided written informed con-
sent to participate in the study.
(e diagnosis of type 2 DM was established by an ex-
perienced endocrinologist based on the American Diabetes
Association criteria [5] (Supplementary Table S1), and only
patients without diabetic retinopathy (at least 12months
prior to recruitment) were eligible for the study. (e In-
ternational Clinical Disease Severity Scale for DR [6] was
used for classification of any diabetic changes observed in
our patients. (is scale describes five stages that are rec-
ognized being the first of all “no apparent retinopathy.” As
the name implies, there are no diabetic fundus changes. (e
second stage is “mild nonproliferative retinopathy” (NPDR),
characterized by the presence of a few microaneurysms.
(ere is a third stage, which is “moderate NPDR” and a
fourth stage “severe NPDR.” (e final stage is “proliferative
diabetic retinopathy” (PDR). Only patients with no apparent
retinopathy (based on methodical funduscopy and OCT
scans) were included in our study.
(e endocrine evaluation was performed by a trained
specialist from the Endocrine and Nutrition Department
of Miguel Servet University Hospital and provided de-
mographic and disease-related parameters. Age at the
time of diagnosis, disease duration, prescribed treatments
(for DM2 and other comorbidities), presence of micro-
and macrovascular complications (such as cardiovascular
disease, cerebrovascular disease, diabetic neuropathy, or
diabetic nephropathy), and presence of conditions related
to chronic complications in DM (such as arterial hy-
pertension, hypercholesterolemia, and obesity) were
recorded. Endocrine variables such as glycosylated he-
moglobin (HbA1C, most recent measured levels),
microalbumin/creatinine ratio, and total, HDL (high-
density lipoprotein), and LDL (low-density lipoprotein)
cholesterol levels were obtained via blood analysis during
routine checkups and recorded for the study. Arterial
blood pressure and body mass index (BMI) were also
checked. Subjects with arterial blood pressure levels of>140/90mmHg or under current hypotensive treatment
were classified as “hypertensive”; subjects with a calcu-
lated BMI of ≥25 were classified as “overweight/obese.”
Smoking habit in patients and controls was also
registered.
Inclusion criteria were confirmed type 2 DMdiagnosis of
at least 6months, best-corrected visual acuity (BCVA) of 0.4
or higher (using a Snellen chart) in each eye to allow the
performance of the protocol, and intraocular pressure less
than 21mmHg. Exclusion criteria were the presence or past
history of diabetic retinopathy, confirmed by indirect fun-
duscopy or retinography images, presence of significant
refractive errors (≥5 diopters of spherical equivalent re-
fraction or 3 diopters of astigmatism), intraocular pressure≥21mmHg, media opacifications, concomitant ocular dis-
eases, including history of glaucoma or retinal pathology,
and systemic conditions that could affect the visual system,
including neurodegenerative disorders such as Parkinson’s
disease, multiple sclerosis, or dementia. Healthy controls
had no record nor evidence of ocular or neurologic disease of
any kind; their BCVA was >20/30 based on the Snellen scale.
Only one eye per patient was selected at random and
incorporated.
A complete ophthalmic evaluation that included pu-
pillary, anterior segment, and funduscopic examination was
performed in all subjects. We performed structural analysis
of the retina using spectral domain (SD) optical coherence
tomography (OCT) with the Spectralis OCT (Heidelberg,
Germany), by three different applications: the Fast macular
cube, for macular analysis, and the RNFL Glaucoma and
RNFL-N Axonal Analytics, for peripapillary evaluation of
the RNFL thickness. Part of this protocol was previously
described by our team elsewhere [7].
A blue quality bar in the image indicates signal
strength (range is 0–40, where 0 is categorized as poor
quality and 40 as excellent). We included images with a
score higher than 25 in analyses. Images were obtained
using the image alignment eye-tracking software (Tru-
Track, Heidelberg Engineering) to acquire measurements
of the nine ETDRS macular areas. Macular full retinal
thickness, ganglion cell layer (GCL) thickness, and RNFL
thickness were obtained using the Spectralis segmentation
software. We also obtained measurements of the RNFL in
the peripapillary area using the Glaucoma application
(RNFL-G) and the Axonal Analytics application (RNFL-
N). (e RNFL thickness was measured around the disc
with 16 average consecutive circular B-scans. (e RNFL-
N system places the temporal region of the scan in the
center of the viewing window for better analysis of axonal
loss in the papillomacular bundle (PMB), as seen in pa-
tients with neurologic diseases such as multiple sclerosis.
(e RNFL thickness graph for the RNFL-N scans reveals
the scan results in the order of nasal-inferior-temporal-
superior-nasal sectors. (is protocol also provides 2
neuro-ophthalmologic parameters: the PMB thickness
and the nasal/temporal (N/T) ratio. (e additional PMB
sector is displayed and classified in the pie chart of the
thickness map. (e parameter N/T ratio is defined as the
mean RNFL thickness in the nasal quadrant divided by the
mean RNFL thickness in the temporal quadrant. (e
parameters registered in the RNFL analysis were average
thickness and thickness for six-disc sectors (superonasal,
nasal, inferonasal, inferotemporal, temporal, and
superotemporal).
2.1. Statistical Analysis. We performed all data analyses
using SPSS software version 20.0 (SPSS Inc., Chicago, IL).
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All quantitative variables were expressed in mean and
standard deviation (SD). All qualitative variables were
expressed in number of cases and percentage. We used the
Kolmogorov–Smirnov test to evaluate sample distribution.
As a result of the normal distribution of the data, differences
between assessments of DM2 patients and healthy subjects
were compared using Student’s t-test. (e linear correlation
between endocrine (age at the time of diagnosis, duration of
the disease, HbA1C, total, HDL, and LDL cholesterol levels,
systolic and diastolic arterial blood pressure, and BMI) and
structural (full retinal thickness in the macular ETDRS areas
and RNFL thickness in the peripapillary area) parameters
was determined using Pearson’s correlation coefficient.
Additionally, we performed a subclassification of sub-
jects, dividing DM2 patients into 2 different groups
depending on the presence/absence of some particular as-
pects: presence/absence of HbA1C levels >7mmol/ml,
disease duration ≥ or < 10 years, presence/absence of
micromacrovascular complications, presence/absence of
obesity, and presence/absence of hypertension. To avoid any
confounding factor, the presence of smoking habit was
analyzed and compared between controls and patients and
also between subgroup of DM patients (smokers vs. non-
smokers). We compared results from the structural analysis
of the retina between both groups using Student’s t-test.
Values of p less than 0.05 were regarded as indicators of
statistical significance. In order to avoid a high false-positive
rate, the Bonferroni correction for multiple tests was cal-
culated and the corrected p values were added to the pre-
viously calculated data (see tables).
3. Results
Sixty eyes of 60 patients with a mean age of 61.60± 9.40 years
and 60 eyes of 60 healthy individuals with a mean age of
60.15± 7.05 were included in the study. (ere were 22 fe-
males (37%) and 38 (63%) males in the patient group and 36
females (60%) and 24 (40%) males in the control group.
Patients and controls did not show significant differences in
the four confounding factors considered: age (p � 0.341),
gender (p � 0.220), intraocular pressure (p � 0.132), and
smoking habit (p � 0.439). Disease duration in the group of
patients was 12.62 years (SD� 7.29) (Supplementary
Table S2). All demographic and endocrinology variables are
displayed in Supplementary Table S1.
3.1. Structural Analysis. Structural measurements of the
macular thickness provided by the Fast macular cube ap-
plication showed significant retinal thinning in patients with
DM2 compared with healthy subjects in all measured
ETDRS areas (Table 1). Additionally, the ganglion cell layer
was reduced in patients in all ETDRS sectors except in the
center. (e RNFL analysis revealed a significant reduction
affecting the outer inferior sector (37.94± 6.08 μm in pa-
tients vs. 40.29± 6.33 μm in controls, p � 0.033); however,
no significant differences were observed in the other ETDRS
areas.
(e RNFL-G application demonstrated a significant RNFL
thinning in DM patients in the average (95.93±12.10μm in
patients vs. 102.30±9.22μm in controls, p � 0.002), inferior
(123.85±18.91μm in patients vs. 135.50±17.01μm in controls,
p � 0.001), temporal (68.42±10.96μm vs. 74.17±15.58μm,
respectively, p � 0.013), and inferotemporal (135.10±20.44μm
vs. 149.85± 21.17μm, p< 0.001) areas (Table 2).(e same areas
were significantly reduced when measured with the RNFL-N
Axonal Analytics application (p � 0.001). Additionally, a sig-
nificant thinning in the average thickness (97.12±12.29μm vs.
103.69±9.55μm, p � 0.001) of the RNFL was observed in
patients with this application.(e PMBwas reduced in patients
compared to controls (53.27±8.31μm vs. 58.10±10.50μm,
p � 0.006) (Table 2).
No significant correlations were observed between the
endocrine variables and the retinal structural measurements
obtained with Spectralis OCT (p> 0.05).
Table 1: Mean and standard deviation (in parentheses) of full
retinal, ganglion cell layer, and retinal nerve fiber layer thickness (in
microns) in the macular area, measured with Spectralis OCT in
healthy controls and patients with DM2.
Macular parameters Healthy DM2 pMean (±SD) Mean (±SD)
Total thickness
Center 282.88 (±18.23) 275.62 (±19.18) 0.035
Inner superior 350.82 (±11.51) 335.38 (±14.77) <0.001∗
Inner nasal 355.23 (±11.94) 337.77 (±15.67) <0.001∗
Inner inferior 347.37 (±10.64) 331.67 (±14.79) <0.001∗
Inner temporal 338.13 (±9.66) 323.40 (±14.79) <0.001∗
Outer superior 302.20 (±14.76) 291.90 (±14.73) <0.001∗
Outer nasal 318.38 (±13.42) 307.33 (±14.29) <0.001∗
Outer inferior 289.48 (±13.05) 279.32 (±14.25) <0.001∗
Outer temporal 288.08 (±13.67) 280.13 (±14.03) 0.002∗
GCL thickness
Center 16.53 (±6.01) 16.63 (±4.18) 0.908
Inner superior 54.17 (±4.23) 49.59 (±5.99) <0.001∗
Inner nasal 53.90 (±4.78) 48.00 (±6.48) <0.001∗
Inner inferior 54.29 (±3.98) 48.96 (±5.98) <0.001∗
Inner temporal 49.44 (±4.18) 43.63 (±6.49) <0.001∗
Outer superior 35.97 (±3.22) 33.56 (±3.22) <0.001∗
Outer nasal 39.16 (±3.28) 36.50 (±3.76) <0.001∗
Outer inferior 33.38 (±3.24) 31.85 (±3.71) 0.014
Outer temporal 36.38 (±3.76) 33.91 (±4.68) 0.001∗
Total volume 1.11 (±0.10) 1.03 (±0.75) <0.001∗
RNFL thickness
Center 13.12 (±1.67) 13.02 (±1.66) 0.752
Inner superior 23.73 (±2.89) 23.89 (±2.89) 0.782
Inner nasal 21.25 (±2.35) 20.95 (±2.68) 0.502
Inner inferior 25.70 (±3.10) 24.67 (±3.09) 0.065
Inner temporal 17.55 (±1.61) 17.64 (±1.56) 0.742
Outer superior 37.09 (±4.99) 36.69 (±6.76) 0.700
Outer nasal 49.34 (±7.45) 47.45 (±7.10) 0.139
Outer inferior 40.29 (±6.33) 37.94 (±6.08) 0.033
Outer temporal 19.31 (±1.64) 19.39 (±1.63) 0.781
Total volume 0.92 (±0.10) 0.89 (±0.10) 0.137
Bold letters indicate statistical significance (p< 0.05). Asterisks mark sta-
tistical significance using Bonferroni correction (p< 0.005). DM, diabetes
mellitus; SD, standard deviation; GCL, ganglion cell layer; RNFL, retinal
nerve fiber layer.
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3.2. SubgroupAnalysis. Diabetic patients were divided into 2
different groups depending on the presence or absence of a
selected variable and then compared.
Patients with poor metabolic control (HbA1C> 7;
n� 28) presented reduced retinal thickness in the nasal
ETDRS macular sectors (inner nasal, p � 0.022; outer nasal,
p � 0.013), in the superior RNFL sector (p � 0.034 with
Glaucoma application), and superonasal RNFL sector
(p � 0.003 with Glaucoma application and p � 0.019 with
Axonal Analytics application) (Table 3).
Patients with disease duration of at least 10 years (n� 38)
presented a reduction in macular thickness in the outer
superior (p � 0.008) and outer temporal (p � 0.004) areas of
the ETDRS analysis compared to those with disease duration
of less than 10 years (n� 22). (e RNFL was thinner in the
longer disease duration group in the superior (Axonal,
p � 0.019), inferior (Glaucoma, p � 0.036), superotemporal
(Glaucoma, p � 0.029; Axonal, p � 0.008), and inferotem-
poral (Glaucoma, p � 0.012) sectors (Table 4).
Patients with the presence of chronic vascular compli-
cations of diabetes (n� 21) presented a reduction of the
temporal sector of the RNFL thickness (Glaucoma,
p � 0.032; Axonal, p � 0.019). (e PMB was also thinner
(p � 0.019) in these patients compared to those without
chronic vascular complications (n� 39) (Table 5).
Patients with obesity (n� 56) were compared with pa-
tients without obesity (n� 4). Macular external sectors
(superior and temporal) were reduced in obese patients
(308.25± 12.10 in normal weight vs. 290.73± 14.29 in obese
patients, p � 0.004; 301.50± 8.27 vs. 278.61± 13.11,
p< 0.001, respectively). No significant reductions were
observed in the peripapillary area between both groups.
(e comparison between patients with/without hyper-
tension, and smoker and nonsmoker patients did not show
any significant differences in the structural variables.
Table 2: Structural measurements obtained with Spectralis OCT in
healthy controls and patients with type 2 diabetes mellitus (DM2)
without diabetic retinopathy.
Peripapillary
measurements
Healthy DM2
pMean (±SD) Mean (±SD)
RNFL Glaucoma
Average 102.30 (±9.22) 95.93 (±12.10) 0.002∗
Superior 123.42(±16.58) 118.98(±19.37) 0.180
Nasal 75.92 (±15.29) 72.48 (±14.84) 0.214
Inferior 135.50(±17.01) 123.85(±18.91) 0.001∗
Temporal 74.17 (±15.58) 68.22 (±9.73) 0.013
Superotemporal 137.27(±16.77) 132.10(±21.76) 0.148
Inferotemporal 149.85(±21.17) 135.10(±20.44) <0.001∗
Superonasal 109.57(±22.76) 105.85(±22.89) 0.374
Inferonasal 121.15 (±24.61) 112.60(±23.81) 0.055
RNFL Axonal Analytics
Average 103.69 (±9.55) 97.12 (±12.29) 0.001∗
Superior 125.63(±17.02) 120.18(±18.95) 0.102
Nasal 77.98 (±14.18) 74.27 (±15.38) 0.173
Inferior 136.97(±17.41) 125.50(±20.14) 0.001∗
Temporal 73.98 (±13.33) 68.42 (±10.96) 0.014
Superonasal 112.59(±22.79) 107.53(±21.35) 0.214
Inferonasal 123.68(±23.26) 114.65(±24.80) 0.043
Superotemporal 138.66(±18.20) 132.82(±22.22) 0.120
Inferotemporal 150.27(±22.38) 136.35(±21.08) 0.001∗
Papillomacular
bundle 58.10 (±10.50) 53.27 (±8.31) 0.006
Nasal/temporal index 1.10 (±0.32) 1.11 (±0.29) 0.793
Bold letters indicate p< 0.05. Asterisks mark significant values according to
Bonferroni corrections for multiple comparisons. DM2, type 2 diabetes
mellitus; RNFL: retinal nerve fiber layer; SD, standard deviation.
Table 3: Structural measurements obtained with Spectralis OCT in
patients with type 2 diabetes mellitus (DM2) with glycated he-
moglobin (HbA1C) ≤7% and >7%, respectively.
HbA1C≤ 7 HbA1C> 7
p
Mean SD Mean SD
Macular thickness
Central 279.03 14.53 271.71 23.06 0.142
Inner superior 338.66 14.24 331.64 14.73 0.066
Inner nasal 342.06 13.73 332.86 16.52 0.022
Inner inferior 334.03 13.83 328.96 15.63 0.188
Inner temporal 325.78 13.39 320.68 16.06 0.185
Outer superior 294.63 13.73 288.79 15.45 0.127
Outer nasal 311.56 12.84 302.50 14.55 0.013
Outer inferior 281.31 12.96 277.04 15.51 0.249
Outer temporal 282.81 13.66 277.07 14.05 0.115
pRNFL Glaucoma
Average 98.19 9.15 93.36 14.53 0.124
Superior 123.91 16.59 113.34 21.03 0.034
Nasal 75.44 11.89 69.11 17.22 0.100
Inferior 125.58 14.87 121.88 22.80 0.454
Temporal 67.44 10.52 69.11 8.85 0.512
Superotemporal 134.00 17.98 129.93 25.58 0.474
Inferotemporal 136.84 15.54 133.11 25.05 0.485
Superonasal 113.81 22.11 96.75 20.57 0.003∗
Inferonasal 114.31 22.63 110.64 25.36 0.556
pRNFL Axonal Analytics
Average 99.69 9.23 94.18 14.67 0.083
Superior 124.39 15.78 115.36 21.29 0.065
Nasal 77.19 12.85 70.93 17.48 0.117
Inferior 128.47 16.06 122.11 23.83 0.225
Temporal 68.44 11.41 68.39 10.62 0.988
Superonasal 113.50 20.12 100.71 20.99 0.019
Inferonasal 117.38 24.35 111.54 25.38 0.367
Superotemporal 135.28 19.50 130.00 25.05 0.363
Inferotemporal 139.56 15.96 132.68 25.54 0.210
Papillomacular bundle 52.25 8.48 54.43 8.11 0.315
Nasal/temporal index 1.16 0.28 1.05 0.30 0.147
Bold letters indicate p< 0.05. Asterisks mark significant values according to
Bonferroni corrections for multiple comparisons. DM2, type 2 diabetes
mellitus; pRNFL: peripapillary retinal nerve fiber layer; SD, standard
deviation.
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4. Discussion
We evaluated retinal changes in 60 patients with type 2 DM
without any sign of diabetic retinopathy using spectral
domain OCT. Some authors suggested that a neuropathy (a
totally different process from the typical vascular compli-
cations observed in diabetic retinopathy) might be causing
ocular degeneration in patients with DM [1]. It was sug-
gested that neuropathic changes might precede microvas-
cular alterations in these patients [4]; however, the possible
correlation between neuropathy and vasculopathy is still
unknown. Funduscopic alterations such as microaneurysms
and hemorrhages which are present at early stages in di-
abetic retinopathy might be preceded by other vascular
alterations that are not observable in a routine exam. (us,
preclinical diabetic retinopathy might be caused by changes
in the caliper of retinal vessels or in the regulation of retinal
blood flow [8–10]. However, changes affecting retinal
neurons have also been observed, such as increased apo-
ptosis of the retinal ganglion cells and activation of the
microglia [11–13] without signs of vascular changes.
OCT studies evaluating whether alterations affecting
the RNFL and other retinal layers preceded any vascular
changes in DM patients obtained opposite results
[3,14–18], but a recent meta-analysis suggested this could
be the case [19]. In our study, we observed an important
reduction in macular thickness affecting all sectors of the
ETDRS map. Early clinical studies using time domain OCT
pointed to greater macular thickness in subjects with DM
(with and without diabetic retinopathy) compared to
controls [20]. More recent research suggested a similar
thickness [21, 22] or significant reduction in the macular
area in DM patients without diabetic retinopathy [23–25],
being the latter supported by our own results. A possible
explanation for the different obtained results concerning
macular measurements is that macular thickness (affected
by macular edema) in DM patients varies greatly with
disease evolution and does not have a uniform behavior,
and vascular alterations might mask other concomitant
neurodegenerative processes affecting the same retinal area
[26, 27]. Segmentation of the different macular layers in
patients with DM presented different results among
studies: recent studies [3, 17, 28, 29] demonstrated a re-
duction in the macular GCL in patients with DM (type 1 in
Scarinci and Gundogan studies) without diabetic reti-
nopathy, but some of them [28, 29] could not find any
differences in the macular RNFL thickness between groups.
Another recent study found a reduction in the macular
RNFL and GCL in type 2 DM without diabetic retinopathy,
but changes in the RNFL thickness were not significant
after age correction for the diabetic group [30]. In our
patients (type 2 DM without diabetic retinopathy), we
observed a reduction in the GCL thickness affecting all
sectors (except for the fovea), but barely no differences were
observed in the macular RNFL thickness, supporting
previously mentioned studies [28–30]. (ese results sug-
gest that neurodegeneration (this is, degeneration of the
ganglion cells) is present in early stages of DM, but axonal
loss in the macular area might not be detectable simulta-
neously. Macular evaluation in DM patients without di-
abetic retinopathy, however, should be analyzed with
caution. According to some authors, retinal damage caused
by disease progression might trigger an immune-mediated
response that leads to intra- and extracellular inflammation
and macular edematous changes. (us, macular thickness
(or its individual layers) might not accurately reflect
neurodegenerative changes in these patients.
(e peripapillary area contains a higher density of axons
(RNFL) compared to the macular area, and therefore, it
should be considered an optimal location to evaluate axonal
loss in DM patients. (e peripapillary RNFL in our patients
was assessed using 2 different OCT applications: the most
frequently used Glaucoma application (RNFL-G) and the
Axonal Analytics application (RNFL-N). (e latter was
specifically designed for the evaluation of neurodegenerative
Table 4: Structural measurements obtained with Spectralis OCT in
patients with type 2 diabetes mellitus with disease duration of <10
and ≥10 years, respectively.
Disease
duration <10
years
Disease
duration ≥10
years p
Mean SD Mean SD
Macular thickness
Central 274.77 16.12 276.11 20.94 0.798
Inner superior 338.91 13.57 333.34 15.22 0.161
Inner nasal 339.64 15.13 336.68 16.07 0.487
Inner inferior 334.27 13.22 330.16 15.60 0.303
Inner temporal 327.09 10.51 321.26 16.54 0.143
Outer superior 298.45 12.53 288.11 14.71 0.008
Outer nasal 309.45 13.23 306.11 14.91 0.386
Outer inferior 282.95 12.05 277.21 15.12 0.133
Outer temporal 286.82 11.24 276.26 14.15 0.004∗
pRNFL Glaucoma
Average 98.91 9.77 94.21 13.08 0.149
Superior 123.36 15.85 116.43 20.92 0.184
Nasal 73.36 12.53 71.97 16.16 0.730
Inferior 130.52 16.29 119.99 19.43 0.036
Temporal 68.18 11.18 68.24 8.95 0.983
Superotemporal 140.09 19.21 127.47 22.03 0.029
Inferotemporal 143.73 15.05 130.11 21.63 0.012
Superonasal 106.64 20.03 105.39 24.65 0.842
Inferonasal 117.32 27.17 109.87 21.54 0.246
pRNFL Axonal Analytics
Average 100.23 10.07 95.32 13.20 0.137
Superior 127.66 17.14 115.84 18.79 0.019
Nasal 76.27 13.61 73.11 16.38 0.447
Inferior 130.16 16.33 122.80 21.80 0.175
Temporal 66.95 10.62 69.26 11.20 0.436
Superonasal 112.68 21.97 104.55 20.68 0.157
Inferonasal 118.82 27.70 112.24 23.00 0.326
Superotemporal 142.64 21.07 127.13 21.10 0.008
Inferotemporal 141.50 14.36 133.37 23.80 0.151
Papillomacular bundle 51.05 8.39 54.55 8.10 0.116
Nasal/temporal index 1.16 0.26 1.08 0.31 0.301
Bold letters indicate p< 0.05. Asterisks mark significant values according to
Bonferroni corrections for multiple comparisons. DM2, type 2 diabetes
mellitus; pRNFL: peripapillary Rretinal nerve fiber layer; SD, standard
deviation.
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changes in the peripapillary area [31, 32]. In our patients, the
RNFL was found to be reduced compared to controls, not
only in average but especially in the inferotemporal sectors.
(e papillomacular bundle was also reduced in patients,
suggesting a degeneration of the axonal path between the
optic disc and the macular ganglion cells. (ese results also
present anatomic correspondence with the distribution of
the macular ganglion cells, whose axons correspond to the
RNFL of the temporal and inferior sectors of the optic disc.
Our results support previous studies in which a reduction
in the average RNFL thickness was observed in patients with
DM2 without diabetic retinopathy [2, 3, 22, 33, 34]. Further
RNFL damage was demonstrated by Carpineto et al. [35], who
observed a reduction in the RNFL affecting all peripapillary
quadrants. However, a reduction affecting the inferior
quadrant was only demonstrated by Carpineto et al. [35] and
Salvi et al. [3], which included the largest sample sizes. (e
affectation of the temporal sectors was barely reported in
previous studies [35], and most important studies on this
matter did not find differences affecting the temporal
quadrant. Since the inferior sector is most frequently affected
by hypoxia, it was reasonable to find a significant reduction in
this quadrant. (e reduction in the temporal areas might
suggest the presence of neurodegeneration by different causes
other than hypoxia, similarly to those observed in neurode-
generative diseases [36, 37].
One of the largest studies on OCT changes in DM pa-
tients concluded that retinal thinning in DM patients is
caused by both vascular alterations and neurodegeneration,
suggesting 2 different phenotypes for DM, one vascular (in
which neurodegeneration is not present or has a minimum
role) and the other (up to 60% of patients) more prone to
neurodegeneration without vascular alterations [1]. Addi-
tionally, this study demonstrated that the association be-
tween OCTchanges and alterations in the electroretinogram
was stronger in cases where vasculopathy was present.
However, it did not establish whether microvascular (sub-
clinical) alterations played a significant role in the patho-
genesis of the retinal changes in the neurodegenerative
phenotype. In our study, patients without diabetic
Table 5: Structural measurements obtained with Spectralis optical coherence tomography in patients with type 2 diabetes mellitus, with and
without vascular complications.
Without complications With complications
p
Mean SD Mean SD
Macular thickness
Central 278.23 15.19 270.76 24.68 0.152
Inner superior 336.41 13.48 333.48 17.11 0.468
Inner nasal 338.87 15.04 335.71 16.95 0.461
Inner inferior 332.49 15.11 330.14 14.41 0.563
Inner temporal 323.90 14.89 322.48 14.93 0.726
Outer superior 291.49 14.86 292.67 14.82 0.770
Outer nasal 306.74 14.65 308.43 13.90 0.667
Outer inferior 280.00 15.68 278.05 11.36 0.617
Outer temporal 278.85 14.11 282.52 13.89 0.337
pRNFL Glaucoma
Average 97.36 14.27 93.29 5.80 0.217
Superior 121.78 22.13 113.76 11.53 0.127
Nasal 72.79 16.01 71.90 12.71 0.827
Inferior 124.49 22.29 122.67 10.40 0.725
Temporal 70.18 9.95 64.57 8.36 0.032
Superotemporal 135.15 24.58 126.43 14.02 0.140
Inferotemporal 135.54 23.83 134.29 12.34 0.823
Superonasal 108.41 24.43 101.10 19.39 0.241
Inferonasal 113.44 26.71 111.05 17.68 0.714
pRNFL Axonal Analytics
Average 98.59 14.51 94.38 5.78 0.208
Superior 122.86 21.36 115.19 12.35 0.136
Nasal 74.54 16.64 73.76 13.08 0.854
Inferior 125.86 23.62 124.83 11.65 0.853
Temporal 70.82 11.14 63.95 9.28 0.019
Superonasal 109.85 23.38 103.24 16.60 0.256
Inferonasal 114.85 27.77 114.29 18.68 0.934
Superotemporal 135.87 24.28 127.14 16.87 0.148
Inferotemporal 136.87 24.91 135.38 11.41 0.796
Papillomacular bundle 55.23 8.19 49.62 7.40 0.011
Nasal/temporal index 1.08 0.32 1.17 0.23 0.236
Bold letters indicate p< 0.05. Asterisks mark significant values according to Bonferroni corrections for multiple comparisons. DM2, type 2 diabetes mellitus;
pRNFL: peripapillary retinal nerve fiber layer; SD, standard deviation.
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retinopathy but with chronic systemic vascular complica-
tions presented a further reduction of the temporal quadrant
of the RNFL and the papillomacular bundle, suggesting that
systemic ischaemia might indeed contribute to further
damage in the neurodegenerative phenotype. Additionally,
when metabolic control was assessed, patients with worse
HbA1C levels presented a further reduction of the superior
and nasal sectors; when disease duration was compared, a
further reduction of the superior sectors was observed.(ese
results might suggest that the presence of other different
factors might also contribute to neuronal damage in these
patients.
Our study presents different limitations: (e sample
selected for the present study includes subjects with different
levels of disease duration and systemic vascular complica-
tions. However, we believe it is a fairly representative sample
of the diabetic population in our society. Another limitation
is the presence of different confounding factors associated
with type 2 DM patients, such as hypertension and smoking
habit. (e presence of smoking habit was compared between
patients and controls to avoid bias; additionally, subgroups
of patients were compared to analyze the possible effect on
structural alterations caused by these 2 variables. Since no
differences were found, we assumed hypertension and
smoking habit could be ruled out as confounding factors in
our patients.
A secondary limitation to our study is the unavailability
of new more precise devices such as OCT angiography.
Additionally, a longitudinal follow-up of these patients
would be needed to establish the influence of hypertension,
obesity, systemic ischaemia, and so on in the development
of DR.
Our results suggest that in patients with type 2 DM
without diabetic retinopathy and good metabolic control, a
neurodegeneration is present affecting especially neurons
in the macular area and the RNFL in the temporal and
inferior sectors of the optic disc. Additionally, the results
obtained in our patients suggest that subclinical ischaemia,
along with other metabolic factors, might be an important
contributory factor to neurodegeneration in these patients.
Further longitudinal studies are needed to establish the
possible role of other systemic complications of DM (es-
pecially ischaemia) in the pathogenesis of retinal
neurodegeneration.
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